No products in the basket.
ADVERTISEMENT
Craft Health Secures Pre-Series A2 Funding to Revolutionize Compounding Pharmacy with 3D Printing Technology.
Singapore,13
May 2024 — Craft Health, a pioneer in the healthcare industry specializing in
the automation of mass customization through its cutting-edge 3D printing
platform, today announced the successful close of its Pre-Series A2 funding
round. Valuence Ventures led the round with significant participation from
Mistletoe Singapore, an existing investor, and an angel investor. This latest funding
underscores the confidence investors have in Craft Health’s vision to
revolutionize compounding pharmacy on a global scale.
The fresh
capital will expedite Craft Health’s commercial trajectory by further
developing its proprietary 3D printing platform designed to streamline and automate
the mass customization of pharmaceuticals. By harnessing the power of its 3D
printing platform, Craft Health aims to introduce unprecedented levels of
efficiency, precision, and customization to the compounding pharmacy sector,
meeting the unique needs of patients with tailored medication solutions.
“We
are delighted to bolster our investor base with partners who share our
deep-tech vision and can impart their wealth of knowledge, experience, and
network to scale Craft Health. This round of funding will fine-tune our commercialization
strategy, refine our product offerings, and set the stage for our anticipated
Series A” said Dr Goh Wei Jiang, co-founder and CEO of Craft Health.
“We
are thrilled to announce our investment in Craft Health, a pioneer in
leveraging 3D printing technology for compounding pharmacy. Craft Health’s
innovative approach aligns perfectly with our mission to support ventures that
redefine industries and improve lives. We are confident in their potential to
revolutionize personalized medicine and look forward to their continued growth
and success in transforming patient care globally.” said Dr. Gene Cho, a
General Partner of Valuence Ventures. “Craft Health’s innovative use of 3D
printing technology in compounding pharmacy not only positions the company at
the forefront of healthcare innovation but also aligns perfectly with our
investment strategy of supporting ventures that are poised for significant
impact and growth. We are confident in Craft Health’s vision and their ability
to lead a new era in personalized medicine, especially in the area of advanced
materials innovation.”
Mistletoe
Singapore also expressed strong support for Craft Health’s mission and its
recent funding success. “Having supported Craft Health from its early
stages, we have witnessed first-hand the dedication and innovation that the
team brings to the healthcare industry. This additional funding will
undoubtedly propel the company towards achieving its commercial goals, and we
are excited to continue our journey with Craft Health as it endeavours to
revolutionize the way pharmaceuticals are customized and dispensed.” Added
Mr Atsushi Taira, Managing Director of Mistletoe Singapore.
Since
2019, Craft Health has developed an end-to-end 3D printing platform for
nutraceuticals and pharmaceuticals, integrating the 3D printer (CraftMake™),
3D printing software (CraftControl™), 3D printable formulations (CraftBlends™)
and one of the world’s first semi-solid paste extrusion-based 3D printing
database for oral dosage forms (CraftDatabase™). Craft Health’s
technology platform is based on the heat and ultraviolet light (UV) light free
semi-solid paste extrusion technique and can incorporate a wide variety of
active ingredients from small molecules to biological molecules. Craft Health
has since commercialized its 3D printing platform, working with compounding
pharmacies, academics, nutraceutical start-ups and MNCs.
Craft
Health’s commitment to innovation in healthcare through its 3D printing
platform represents a significant leap forward in making personalized medicine
more accessible and effective for patients worldwide. With this new round of
funding, Craft Health is poised to make substantial advancements in the
commercialization of its technology, setting a new standard for precision and
patient-centred care in the pharmaceutical industry.
This content was prepared by our news partner, VRITIMES. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Thailand Business News
